Prescribing Information
PATIENT SITE
DARZALEX
FASPRO
®
DOSING & ADMINISTRATION GUIDE
DARZALEX
®
DOSING & ADMINISTRATION GUIDE
GET IN TOUCH
PRODUCT USE
INDICATIONS AND DOSING
Newly Diagnosed
DRd
DVMP
DVTd
Relapsed or Refractory
DRd
DPd
DKd
DVd
Monotherapy
NCCN RECOMMENDATIONS
ADMINISTRATION
CLINICAL TRIALS
DRd: MAIA
DARZALEX
FASPRO
®
: COLUMBA
ADDITIONAL TRIALS
RESOURCES
PRACTICE SUPPORT
PATIENT SUPPORT
MECHANISM OF ACTION
GET IN TOUCH
Q&A
FOR APP
s
AND NURSES
PRESCRIBING INFORMATION
DARZALEX
FASPRO
®
Prescribing Information
DARZALEX
FASPRO
®
la información de prescripción
DARZALEX
®
Prescribing Information
Important Safety Information
DARZALEX
FASPRO
®
Important Safety Information
DARZALEX
®
Important Safety Information
Contact Us
1-800-JANSSEN
Email Medical Information Center
Search Janssen MD
CONTACT US
Dosing & Administration Guide
DARZALEX
FASPRO
®
Dosing & Administration Guide
DARZALEX
®
Dosing & Administration Guide
PATIENT SITE
JANSSEN MYELOMA TREATMENTS
For US Healthcare Professionals
Site Map
Home
Site Map
Product Use
Indications and Dosing
Newly Diagnosed
DRd
DVMP
DVTd
Relapsed or Refractory
DRd
DPd
DKd
DVd
Monotherapy
NCCN Recommendations
Administration
Clinical Trials
DRd: MAIA
DARZALEX
FASPRO
®
: COLUMBA
Additional Trials
Resources
Practice Support
Patient Support
Mechanism of Action
Get in Touch
Q&A
For APP
s
and Nurses